What Is Epithalamin? The Pineal Peptide Extract Behind Epitalon
Epithalamin is a bovine pineal gland peptide extract (a cytomedin) developed in Soviet-era Russia, and the parent from which synthetic Epitalon (AEDG) was designed.
Epithalamin is a low-molecular-weight polypeptide complex extracted from the bovine pineal gland, developed in Soviet-era Russia as a 'cytomedin'. It is an undefined animal-tissue extract, not a single molecule, and the synthetic tetrapeptide Epitalon (AEDG) was designed from its amino-acid composition.
Epithalamin sits at the origin of a lineage that has attracted a lot of attention in longevity circles, usually under the name of its synthetic descendant, Epitalon. Where Epitalon is a single defined tetrapeptide, Epithalamin is something older and messier — a crude polypeptide fraction pulled from the pineal glands of cattle, catalogued in the Soviet-era literature as a “cytomedin”. Understanding one requires understanding the other, because the tetrapeptide was quite literally built from the extract. Everything below describes laboratory and literature findings, not use in people or animals.
What is Epithalamin, structurally?
Epithalamin (also written Epithalamine or Epitalamin; Russian trade name Эпиталамин) is a low-molecular-weight polypeptide complex isolated from the bovine pineal gland, or epiphysis. It belongs to a class of tissue extracts that Vladimir Khavinson and Vladimir Morozov called “cytomedins” — peptide fractions drawn from specific organs and proposed to carry tissue-specific regulatory signals. It was developed at the then-Soviet Military Medical Academy in St Petersburg across the 1970s and 1980s, and by 1994 the originating group could already publish a twenty-year retrospective of its work in gerontology and oncology.4
The critical point for anyone comparing Epithalamin to modern research peptides is that it is not a single characterized molecule. It is a heterogeneous mixture. There is no unique amino-acid sequence, no molecular formula, and no CAS number attached to Epithalamin the way there is to a defined peptide. That distinction matters, and it is the through-line of this piece.
How Epithalamin gave rise to Epitalon
The tetrapeptide most people actually encounter — Epitalon, or Epithalon (Ala-Glu-Asp-Gly, AEDG, CAS 307297-39-8) — was not discovered independently. It was reverse-engineered from the extract. A 2025 independent review from Warsaw states the relationship verbatim: Epitalon “was synthesized based on the amino acids composition of Epithalamin, a bovine pineal gland extract.”1 The same derivation is stated in the primary Russian-lineage literature: Sibarov and colleagues wrote that “Tetrapeptide Epitalon is synthesised on the basis of the amino acid composition of pineal peptide extract Epithalamin,”12 and Khavinson’s foundational 2002 monograph frames the tetrapeptide as reproducing the effects of the extract.2
4 Ala-Glu-Asp-Gly — the four residues distilled from a whole-gland extract into one defined synthetic peptide.
This is the same design logic Khavinson’s group applied elsewhere: the thymus extract Thymalin was reduced to short synthetic peptides such as Thymogen and Vilon. Epithalamin to Epitalon follows that template. Later work made the hierarchy explicit — in old rhesus monkeys, Epitalon is described as “a synthetic analogue of the pharmacopoeia drug epithalamin,”13 and reviews of pineal aging routinely pair “the peptides extract of pineal gland epithalamin and synthetic tetrapeptide on its base epithalon”.14
What did the extract reportedly do?
The mechanistic story the originating group proposed centers on melatonin. Aging blunts the pineal’s nocturnal melatonin rhythm; Epithalamin was reported to stimulate the gland to restore it. In old rats, the lifespan effect of Epithalamin was explicitly linked to elevated pineal and serum melatonin.5 On top of that, the literature describes antioxidant/free-radical-scavenging and immunomodulatory activity.
The efficacy data fall into two buckets: animal lifespan/tumor work and small human cohort trials. In fruit flies, mice and rats, Epithalamin was reported to raise mean lifespan by 11–31% and to cut the mortality rate by up to roughly 52%, with the effect attributed to melatonin stimulation and antioxidant action.3 Antitumor rodent work reported reduced total and malignant tumor incidence in irradiated rats,6 lower incidence and multiplicity with longer latency in transplacental nitrosourea-induced tumors,7 and a role in inhibiting mammary carcinogenesis alongside its synthetic analog.8
The tetrapeptide was reverse-engineered from the extract — which is exactly why the extract is best read as history, and the analog as the science.
| Property | Epithalamin (extract) | Epitalon (synthetic) |
|---|---|---|
| Nature | Polypeptide complex (cytomedin) | Single tetrapeptide |
| Sequentie | Undefined / heterogeneous | Ala-Glu-Asp-Gly (AEDG) |
| CAS-nummer | None | 307297-39-8 |
| Bron | Bovine pineal gland | Chemical synthesis |
| Regulatory status | Former Russian pharmacopoeia drug | No FDA/EMA authorization |
Comparison drawn from the cited literature. All entries describe research/reference status only; none of these are consumption or dosing claims.
Human cohort reports
The human data came from the St Petersburg and Kiev groups. The headline elderly-cohort report (266 subjects over 6–8 years) stated that mortality fell 1.6–1.8-fold with Epithalamin, and up to 4.1-fold in a subgroup given Epithalamin plus Thymalin for six years.9 A 12-year study in elderly coronary patients reported 28% lower all-cause and roughly 2-fold lower cardiovascular mortality versus control,10 and a 15-year follow-up (39 Epithalamin vs 40 control patients) reported decelerated cardiovascular aging and a normalized melatonin rhythm.11 Epithalamin itself held Russian/Soviet pharmacopoeia drug status,13 though it carries no FDA or EMA marketing authorization.
An honest read of the evidence
Take those mortality figures with the skepticism they deserve. Nearly all of the efficacy data — animal and human — originate from a single research network: Khavinson, Anisimov and Morozov at the St Petersburg Institute of Bioregulation and Gerontology, together with the Kiev Institute of Gerontology. Independent Western replication of the lifespan and mortality claims is essentially absent. When results this striking come from one lineage over four decades, and the same authors developed the drug, the risk of systematic bias is high, not incidental.
The human trials compound the problem. They are old (1970s–2000s), small-n (the 15-year follow-up compared 39 patients against 40), and published largely in low-visibility Russian journals such as Bulletin of Experimental Biology and Medicine and Neuro Endocrinology Letters. The abstracts report little detail on blinding or randomization, and none meet modern GCP or trial-registration standards. There is no modern, independent, controlled human trial demonstrating a longevity benefit from Epithalamin. Most of the lifespan and antitumor evidence sits in rodents, flies and a handful of aged monkeys.
Then there is the extract itself. Epithalamin is heterogeneous and undefined — batch composition, purity and the identity of the active constituent are not standardized the way a defined peptide’s would be, which complicates both reproducibility and any clean mechanistic attribution. Its bovine-pineal, animal-brain sourcing also raises a genuine safety flag for TSE/prion and immunogenicity that the older literature simply does not address. And tellingly, the modern peer-reviewed work that is independent — the 2025 Warsaw review, for instance1 — concerns the synthetic Epitalon, not the extract. The strongest recent science supports the successor molecule, not Epithalamin itself. Read Epithalamin as historical context for Epitalon, and see the 2025 independent telomerase replication for where the defined-peptide evidence actually stands.
All materials referenced by Condor Research are discussed on a Research Use Only (RUO) basis. Epithalamin is presented here as a literature and reference compound, not a Condor catalogue product, and nothing in this article is a dosing protocol, clinical guidance, or a safety assessment for any organism. The findings described are in-vitro, animal, or historical-cohort observations reported in the cited literature — not use in people.
Condor Research · Wetenschappelijke helpdesk
Atrio Sciences s.r.o., IČO 57 669 651, Nitra (SK) · info@condorresearch.com
- Epithalamin (Эпиталамин) is a low-molecular-weight polypeptide complex extracted from the bovine pineal gland — a 'cytomedin', not a single defined molecule with a CAS number or formula.
- It was developed by V.G. Morozov and V.Kh. Khavinson at the Military Medical Academy in St Petersburg in the 1970s–80s; roughly two decades of study were already summarized by 1994.
- The synthetic tetrapeptide Epitalon (Ala-Glu-Asp-Gly, AEDG; CAS 307297-39-8) was rationally designed from the amino-acid composition of Epithalamin — the same extract-to-analog pattern as Thymalin to Thymogen/Vilon.
- The proposed mechanism is stimulation of pineal melatonin synthesis to restore an age-blunted circadian rhythm, plus reported antioxidant and immunomodulatory effects.
- The originating group reported lifespan gains of 11–31% and lower tumor incidence in flies, mice and rats, and reduced mortality in small elderly-cohort trials — almost all from a single St Petersburg/Kiev research network.
- Epithalamin held Russian/Soviet pharmacopoeia drug status but has no FDA or EMA marketing authorization; the strongest recent independent science concerns the synthetic Epitalon, not the extract.
Where does Epithalamin come from?
It is extracted from the pineal gland (epiphysis) of cattle. That animal-brain origin is one reason it is treated strictly as a research reference material rather than a consumer product, given TSE/prion and immunogenicity considerations that the older literature does not address.
Who developed Epithalamin?
V.G. Morozov and V.Kh. Khavinson at the (then Soviet) Military Medical Academy in St Petersburg, from the 1970s onward. The same group later developed the synthetic peptide bioregulators. See who was Vladimir Khavinson and the broader Khavinson peptide bioregulators program.
Is Epithalamin the same thing as Epitalon?
No. Epithalamin is an undefined polypeptide extract; Epitalon (AEDG) is a single synthetic tetrapeptide designed from the extract's amino-acid composition. They are related as parent and analog, not as identical substances.
What is the proposed mechanism?
The originating group proposed that Epithalamin stimulates pineal melatonin synthesis, restoring an age-blunted circadian rhythm, with additional antioxidant and immunomodulatory effects reported. These are literature-described mechanisms, not established clinical effects.
Is Epithalamin approved as a medicine?
It held Russian/Soviet pharmacopoeia drug status but has no FDA or EMA marketing authorization in the US or EU. A related modern pineal polypeptide complex is described in the literature, but Epithalamin itself is not authorized in Western markets.
How similar is it to the Thymalin story?
Structurally the pattern is identical: a whole-tissue cytomedin extract reduced to short synthetic peptides. Thymalin gave rise to Thymogen and Vilon; Epithalamin gave rise to Epitalon. See what is Thymalin for the thymic parallel.